Phase 4 Osteoarthritis Trial, Recruiting NCT07180979 Sponsor: Poznan University of Medical Sciences Condition: Osteoarthritis
Back to Osteoarthritis

Phase 4 Osteoarthritis Trial, Recruiting

NCT07180979
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 65 years of age or older
  • Your general health has been assessed by a doctor and falls within a certain range of fitness for medical procedures (this is called ASA status I–III — confirm with trial site if unsure which category applies to you)
  • You are scheduled for a planned (non-emergency) hip replacement surgery on one side only, using a specific surgical approach (from the back or side of the hip)
  • You have agreed to take part and provided your written consent

Who may not be able to join:

  • You have a known allergy to either of the medications used in the study (ropivacaine or dexamethasone)
  • You regularly use opioid pain medications at higher doses (more than a certain daily amount — confirm with trial site)
  • You have a blood clotting disorder or an infection near the area where an injection would be given
  • Your body mass index (a measure of weight relative to height) is over 40
  • You already have muscle weakness or nerve problems in the leg or hip being treated
  • You have a memory or thinking condition that would make it difficult for you to understand and agree to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Malgorzata Reysner, Poznan University of Medical Sciences

Phone: +48 61 873 83 03

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Poznan University of Medical Sciences
Registry
ClinicalTrials.gov
Start date
15 September 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Total opioid consumption

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov